← Leaderboards
Suman Srinivasa
Massachusetts General Hospital
$5,199,600
Attributed
$5,199,600
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2017–24$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,199,600 · 2
By mechanism
R01$4,239,550 · 1
K23$960,050 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Steven Kyle Grinspoon$75,757,679
- Guillermo J. Tearney$42,608,505
- Udo Hoffmann$17,171,978
- Ahmed A Tawakol$9,912,063
- Brett E Bouma$16,028,207
Others in their field
Other Emerging Leaders on “Macrophage Activation”
- Markus Bosmann · Boston University Medical Campus$6,657,387
- Laszlo Nagy · Johns Hopkins University$5,953,076
- John R Lukens · University Of Virginia$5,787,762
- Frederic Geissmann · Sloan-Kettering Inst Can Research$5,598,845
- Eti Yoles · Immunobrain Checkpoint Inc.$5,499,685
- Seungmin Hwang · University Of Chicago$4,418,311
Research focus
Macrophage ActivationMetabolicLinkImaging TechniquesInsulin ResistanceInflammatoryFibrosisFda ApprovedHormonesHormonalImmunologicsImmune ActivationIndexingInflammationCardiovascular SystemEndocrinologyCardiovascular HealthFatty Acid Glycerol EstersChronicGeneral PopulationHeart DiseasesCardiacAldosteroneMorbidity - Disease Rate
Grant awards (10)
Avoiding (Heart) Failure: Physiologic-Based Targeting of the RAAS to Treat Subclinical HFpEF among PWH$840,829
R01 · FY2024 · HL · contact PI
Avoiding (Heart) Failure: Physiologic-Based Targeting of the RAAS to Treat Subclinical HFpEF among PWH$842,388
R01 · FY2023 · HL · contact PI
Avoiding (Heart) Failure: Physiologic-Based Targeting of the RAAS to Treat Subclinical HFpEF among PWH$842,357
R01 · FY2022 · HL · contact PI
Avoiding (Heart) Failure: Physiologic-Based Targeting of the RAAS to Treat Subclinical HFpEF among PWH$839,988
R01 · FY2021 · HL · contact PI
Physiologic Investigation of the Renin-Angiotensin-Aldosterone System to Understand Arterial Inflammation in HIV$192,010
K23 · FY2021 · HL · contact PI
Avoiding (Heart) Failure: Physiologic-Based Targeting of the RAAS to Treat Subclinical HFpEF among PWH$873,988
R01 · FY2020 · HL · contact PI
Physiologic Investigation of the Renin-Angiotensin-Aldosterone System to Understand Arterial Inflammation in HIV$192,010
K23 · FY2020 · HL · contact PI
Physiologic Investigation of the Renin-Angiotensin-Aldosterone System to Understand Arterial Inflammation in HIV$192,010
K23 · FY2019 · HL · contact PI
Physiologic Investigation of the Renin-Angiotensin-Aldosterone System to Understand Arterial Inflammation in HIV$192,010
K23 · FY2018 · HL · contact PI
Physiologic Investigation of the Renin-Angiotensin-Aldosterone System to Understand Arterial Inflammation in HIV$192,010
K23 · FY2017 · HL · contact PI